Substitution of arginine 219 by glycine compromises stability, dimerization, and catalytic activity in a G6PD mutant
Issued Date
2023-12-01
Resource Type
eISSN
23993642
Scopus ID
2-s2.0-85179342269
Journal Title
Communications Biology
Volume
6
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Communications Biology Vol.6 No.1 (2023)
Suggested Citation
Zgheib O., Chamchoy K., Nouspikel T., Blouin J.L., Cimasoni L., Quteineh L., Boonyuen U. Substitution of arginine 219 by glycine compromises stability, dimerization, and catalytic activity in a G6PD mutant. Communications Biology Vol.6 No.1 (2023). doi:10.1038/s42003-023-05599-z Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/91524
Title
Substitution of arginine 219 by glycine compromises stability, dimerization, and catalytic activity in a G6PD mutant
Other Contributor(s)
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common enzymopathies in humans, present in approximately half a billion people worldwide. More than 230 clinically relevant G6PD mutations of different classes have been reported to date. We hereby describe a patient with chronic hemolysis who presents a substitution of arginine by glycine at position 219 in G6PD protein. The variant was never described in an original publication or characterized on a molecular level. In the present study, we provide structural and biochemical evidence for the molecular basis of its pathogenicity. When compared to the wild-type enzyme, the Arg219Gly mutation markedly reduces the catalytic activity by 50-fold while having a negligible effect on substrate binding affinity. The mutation preserves secondary protein structure, but greatly decreases stability at higher temperatures and to trypsin digestion. Size exclusion chromatography elution profiles show monomeric and dimeric forms for the mutant, but only the latter for the wild-type form, suggesting a critical role of arginine 219 in G6PD dimer formation. Our findings have implications in the development of small molecule activators, with the goal of rescuing the phenotype observed in this and possibly other related mutants.